Boiler,
I was refering to the Immune response recorded from each drug.
- All 14 patients produced desired cellular immune response
- 4 had stable disease during the assessment period of one year
- 2 patients received ongoing therapy for >40mths
If this is not correct you'd have to take it up with Prima because I sourced it from the latest Investor presentation.
From the Mimosa Project website ~ "Immune response activated in 70% of patients with Abagovomab
SP today, page-76
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |